Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 + Bevacizumab vs Bevacizumab as First-line Maintenance in Ovarian Cancer
NCT07779538Phase 3Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Oct 2026
- Primary completion
- Feb 2030
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Oct 2026; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07779538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07779538.